- Home
- MVST vs AUTL Comparison
MVST vs AUTL Comparison
Compare MVST & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- AUTL
- Stock Information
- Founded
- MVST 2006
- AUTL 2014
- Country
- MVST United States
- AUTL United Kingdom
- Employees
- MVST N/A
- AUTL N/A
- Industry
- MVST Industrial Machinery/Components
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVST Miscellaneous
- AUTL Health Care
- Exchange
- MVST Nasdaq
- AUTL Nasdaq
- Market Cap
- MVST 676.9M
- AUTL 590.8M
- IPO Year
- MVST N/A
- AUTL 2018
- Fundamental
- Price
- MVST $1.17
- AUTL $1.55
- Analyst Decision
- MVST Buy
- AUTL Strong Buy
- Analyst Count
- MVST 3
- AUTL 4
- Target Price
- MVST $3.33
- AUTL $9.15
- AVG Volume (30 Days)
- MVST 3.7M
- AUTL 1.3M
- Earning Date
- MVST 03-31-2025
- AUTL 03-20-2025
- Dividend Yield
- MVST N/A
- AUTL N/A
- EPS Growth
- MVST N/A
- AUTL N/A
- EPS
- MVST N/A
- AUTL N/A
- Revenue
- MVST $370,989,000.00
- AUTL $10,120,000.00
- Revenue This Year
- MVST $19.19
- AUTL $274.71
- Revenue Next Year
- MVST $29.35
- AUTL $239.55
- P/E Ratio
- MVST N/A
- AUTL N/A
- Revenue Growth
- MVST 39.03
- AUTL 496.00
- 52 Week Low
- MVST $0.15
- AUTL $1.52
- 52 Week High
- MVST $2.87
- AUTL $6.31
- Technical
- Relative Strength Index (RSI)
- MVST 34.85
- AUTL 33.58
- Support Level
- MVST $1.16
- AUTL $1.58
- Resistance Level
- MVST $1.33
- AUTL $1.70
- Average True Range (ATR)
- MVST 0.10
- AUTL 0.13
- MACD
- MVST -0.01
- AUTL -0.02
- Stochastic Oscillator
- MVST 19.05
- AUTL 6.06
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.